THERAPY DOSSIER · th-c2d93b821365

Galectin-1 (dimeric form)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27296316 ↗2016Reported benefit

Ligand-mediated Galectin-1 endocytosis prevents intraneural H2O2 production promoting F-actin dynamics reactivation and axonal re-growth.

MouseSpinal cord injuryUnspecified

Model: Acute and chronic spinal cord injury model in vivo, with cultured neurons in vitro

Dimeric galectin-1 lowered hydrogen peroxide levels and restored F-actin dynamics in growth cones via carbohydrate-dependent co-internalisation with PlexinA4, and was associated with axonal re-growth, de novo synapse clustering, re-myelination and functional locomotor recovery in acute and chronic…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…